NeoGenomics, Inc. (NASDAQ:NEO) Q4 2020 Earnings Conference Call February 24, 2021 8:30 AM ET Company Participants Doug VanOort - Chairman, CEO Kathryn McKenzie - CFO Rob Shovlin - President, Clinical Division Bill Bonello - President, Informatics Division Doug Brown - Chief Strategy, CDO Charlie Eidson - Manager, IR Larry Weiss - CMO, Director of R&D George Cardoza - President, Pharma Services Division Lynn Tetrault - LID of Board of Directors Conference Call Participants David Westenberg - Guggenheim Secur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorpor ...

NeoGenomics, Inc. (NASDAQ:NEO) Q3 2020 Results Earnings Conference Call October 27, 2020 8:30 AM ET Company Participants Doug VanOort - Chairman and CEO Kathryn McKenzie - Chief Financial Officer Rob Shovlin - President, Clinical Services Division George Cardoza - President, Pharma Services Division Bill Bonello - President, Informatics Division Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Manager, Investor Relations Conference Call Participants Alex Nowak - Craig-Hallum Ca ...

< NF' NOMICS INVESTOR PRESENTATION August 2020 Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exac ...

NeoGenomics, Inc. (NASDAQ:NEO) Q2 2020 Earnings Conference Call July 28, 2020 8:30 AM ET Company Participants Doug VanOort - Chief Executive Officer Kathryn McKenzie - Chief Financial Officer Rob Shovlin - President, Clinical Division Bill Bonello - President, Informatics Division and Director, Investor Relations George Cardoza - President, Pharma Services Division Larry Weiss - Chief Medical Officer Doug Brown - Chief Strategy and Corporate Development Officer Conference Call Participants Alex Nowak - Crai ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or For the transition period from _________ to __________ Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 12701 Commonwealth Dr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 Indicate by check mark whether the registrant ...